A study conducted in the Netherlands shows that the monoclonal antibody palivizumab significantly reduces wheezing days during premature infants’ first year of life, in addition to preventing severe respiratory syncytial virus (RSV) infection in these high-risk children.
Investigators assigned 429 preterm infants, who were no more than 6 months old and born at a gestational age of 33 to 35 weeks, to receive either palivizumab injections or placebo during RSV season. Until their infants reached their first birthdays, parents reported on the number of days their babies wheezed, along with airway symptoms, doctor or hospital visits, and use of airway drugs. Parents also took a nasopharyngeal swab from infants who had respiratory symptoms that lasted more than 1 day; investigators tested the swabs for the presence of RSV. Median follow-up was 10 months in both study groups.
Infants in the palivizumab group wheezed fewer days than those in the placebo group, with rates of wheezing in the palivizumab group 2.7 percentage points lower than in the placebo group (1.8% vs 4.5%), for a relative reduction of 61%. These effects persisted during the postprophylaxis period, for a relative reduction of 73%. Similarly, the palivizumab group experienced decreased wheezing days outside the RSV season. In addition, the proportion of infants with recurrent wheeze was 10 percentage points lower in patients treated with palivizumab (11% vs 21%). Similarly, the proportion of infants using bronchodilators was lower in the treatment group than in the placebo group (13% vs 23%).
As expected, the study confirmed that infants who were treated with palivizumab had a lower incidence both of RSV-related hospitalization and of medically attended nonhospitalized RSV infection than those who received placebo. Among children with any proven RSV infection, however, no significant differences were seen between the 2 groups in the incidence of wheezing or in the mean number of wheezing days during the first year of life (Blanken MO, et al. N Engl J Med. 2013;368[19]:1791-1799).
COMMENTARY This investigation addresses pediatricians’ age-old, chicken-or-egg question: Does early RSV infection cause later wheezing in childhood or are infants who develop severe symptoms with early RSV preprogrammed to be wheezers? This prospective, randomized, controlled study offers evidence that RSV is the egg rather than the chicken. -Michael Burke, MD
DR BURKE, section editor for Journal Club, is chairman of the Department of Pediatrics at Saint Agnes Hospital, Baltimore, Maryland. He is a contributing editor for Contemporary Pediatrics. He has nothing to disclose in regard to affiliations with or financial interests in any organizations that may have an interest in any part of this article.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.
CDC issues health advisory alert after increases in RSV activity
September 6th 2023Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.
FDA approves Pfizer’s maternal vaccine to prevent RSV in infants
August 21st 2023Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).
Chikungunya vaccine effective in adolescents after phase 3 trial
August 14th 2023Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.
2 Clarke Drive
Cranbury, NJ 08512